What is HC Wainwright’s Estimate for BOLT Q3 Earnings?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Bolt Biotherapeutics in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will earn ($0.33) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.38). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.79 million.

Separately, Stifel Nicolaus reduced their target price on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research report on Tuesday. Five analysts have rated the stock with a hold rating, According to MarketBeat, Bolt Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Trading Down 0.1 %

Bolt Biotherapeutics stock opened at $0.44 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. Bolt Biotherapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.56. The stock has a market cap of $16.82 million, a P/E ratio of -0.26 and a beta of 0.94. The firm’s fifty day moving average price is $0.47 and its 200-day moving average price is $0.55.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of BOLT. FMR LLC raised its position in shares of Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares in the last quarter. Millennium Management LLC bought a new position in Bolt Biotherapeutics in the fourth quarter valued at $25,000. Citadel Advisors LLC purchased a new stake in Bolt Biotherapeutics during the fourth quarter valued at about $42,000. Squarepoint Ops LLC bought a new stake in Bolt Biotherapeutics during the fourth quarter worth about $26,000. Finally, Velan Capital Investment Management LP purchased a new position in shares of Bolt Biotherapeutics in the 4th quarter worth about $27,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.